

# SmartPA Criteria Proposal

<b>Drug/Drug Class:</b>	Fibromyalgia Agents PDL Edit
<b>First Implementation Date:</b>	June 2, 2010
<b>Revised Date:</b>	December 17, 2020
<b>Prepared for:</b>	MO HealthNet
<b>Prepared by:</b>	MO HealthNet/Conduent
<b>Criteria Status:</b>	<input type="checkbox"/> Existing Criteria <input checked="" type="checkbox"/> Revision of Existing Criteria <input type="checkbox"/> New Criteria

## Executive Summary

**Purpose:** The MO HealthNet Pharmacy Program will implement a state specific preferred drug list.

**Why was this Issue Selected:** Fibromyalgia is characterized by chronic widespread pain and heightened painful response to pressure. The underlying cause of fibromyalgia is unknown. Diagnosis is based on expert opinions. It affects 0.5% to 5% of the general population and up to 15.7% in a clinic setting. Clinical guidelines recommend a multidisciplinary approach with short-term use of medication for relief. There are three FDA approved medications for management of fibromyalgia: pregabalin, duloxetine and milnacipran. Current evidence supports the safety and efficacy of the approved agents as monotherapy for up to 6 months for Cymbalta®, Drizalma Sprinkle™, Irenka™ and Lyrica® and up to 3 months for Savella®. Many other agents are used off-label for management of fibromyalgia. Combination therapy of approved or off-label medications can potentially cause severe adverse events, drug interactions and interfere with disease management. Studies also show the efficacy of these agents in managing fibromyalgia decreases over time.

Total program savings for the PDL classes will be regularly reviewed.

Program-specific information:	Preferred Agents	Non-Preferred Agents
	<ul style="list-style-type: none"> <li>Duloxetine 20, 30, 60mg</li> <li>Pregabalin Caps</li> </ul>	<ul style="list-style-type: none"> <li>Cymbalta®</li> <li>Drizalma Sprinkle™</li> <li>Duloxetine 40mg</li> <li>Irenka™</li> <li>Lyrica®</li> <li>Pregabalin Soln</li> <li>Savella®</li> </ul>

**Type of Criteria:**  Increased risk of ADE  Preferred Drug List  
 Appropriate Indications  Clinical Edit

**Data Sources:**  Only Administrative Databases  Databases + Prescriber-Supplied

## Setting & Population

- Drugs class for review: Fibromyalgia Agents
- Age Range: All appropriate MO HealthNet participants 13 years of age or older

## Approval Criteria

- **For Cymbalta: participants aged 13 years of age or older OR**
- Participants aged 18 years of age or older **AND**
- Failure to achieve desired therapeutic outcomes with a trial on 2 preferred agents
  - Documented trial period for preferred agents **OR**
  - Documented ADE/ADR to preferred agents
- For Savella: Documented diagnosis of fibromyalgia in the last 2 years
- For Irenka or Drizalma Sprinkle: Documented diagnosis of depression, anxiety, chronic musculoskeletal pain, or peripheral neuropathy associated with diabetes in the last 2 years
- For Lyrica: Documented diagnosis of fibromyalgia, neuropathy post spinal cord injury, postherpetic neuralgia, partial onset seizures, or peripheral neuropathy associated with diabetes in the last 2 years

## Denial Criteria

- Lack of adequate trial on required preferred agents
- Therapy will be denied if all approval criteria are not met
- After 90 days of fibromyalgia therapy, participants receiving any combination of > 3 of the following drug classes in the last 120 days:
  - Tricyclic Antidepressants (TCA)
  - Selective Serotonin Re-uptake Inhibitors (SSRI)
  - Opioids
  - Skeletal Muscle Relaxants
- **Claim exceeds maximum dosing limitations on the following:**

Drug Description	Generic Equivalent	Maximum Dosing Limitations
CYMBALTA 20 MG CAPSULE	DULOXETINE	2 capsules per day
CYMBALTA 30 MG CAPSULE	DULOXETINE	1 capsule per day
CYMBALTA 60 MG CAPSULE	DULOXETINE	2 capsules per day
DRIZALMA SPRINKLE DR 20 MG CAP	DULOXETINE	1 capsule per day
DRIZALMA SPRINKLE DR 30 MG CAP	DULOXETINE	1 capsule per day
DRIZALMA SPRINKLE DR 40 MG CAP	DULOXETINE	2 capsules per day
DRIZALMA SPRINKLE DR 60 MG CAP	DULOXETINE	2 capsules per day
IRENKA DR 40 MG CAPSULE	DULOXETINE	3 capsules per day
LYRICA 25 MG CAPSULE	PREGABALIN	3 capsules per day
LYRICA 50 MG CAPSULE	PREGABALIN	3 capsules per day
LYRICA 75 MG CAPSULE	PREGABALIN	3 capsules per day
LYRICA 100 MG CAPSULE	PREGABALIN	3 capsules per day
LYRICA 150 MG CAPSULE	PREGABALIN	3 capsules per day
LYRICA 200 MG CAPSULE	PREGABALIN	3 capsules per day
LYRICA 225 MG CAPSULE	PREGABALIN	3 capsules per day
LYRICA 300 MG CAPSULE	PREGABALIN	2 capsules per day
LYRICA 20 MG/ML ORAL SOLUTION	PREGABALIN	30 mL per day
LYRICA CR 82.5 MG TABLET	PREGABALIN	1 tablet per day
LYRICA CR 165 MG TABLET	PREGABALIN	1 tablet per day
LYRICA CR 330 MG TABLET	PREGABALIN	1 tablet per day
SAVELLA 12.5 MG TABLET	MILNACIPRAN	2 tablets per day
SAVELLA 25 MG TABLET	MILNACIPRAN	2 tablets per day

SmartPA PDL Proposal Form

© 2020 Conduent Business Services, LLC. All rights reserved. Conduent™ and Conduent Design™ are trademarks of Conduent Business Services, LLC in the United States and/or other countries.

Other company trademarks are also acknowledged.

SAVELLA 50 MG TABLET	MILNACIPRAN	2 tablets per day
SAVELLA 100 MG TABLET	MILNACIPRAN	2 tablets per day

### Required Documentation

Laboratory results:   
 MedWatch form:

Progress notes:

### Disposition of Edit

Denial: Exception Code "0160" (Preferred Drug List Edit)  
 Rule Type: PDL

### Default Approval Period

1 year

### References

1. Drug Effectiveness Review Project – Drug Class Review: "Drugs for Fibromyalgia", Center for Evidence-Based Policy, Oregon Health & Science University; April 2011; Evidence Scan Update, June 2018.
2. Evidence-Based Medicine and Fiscal Analysis: "Fibromyalgia – Therapeutic Class Review", Conduent Business Services, L.L.C., Richmond, VA; November 2020.
3. Evidence-Based Medicine Analysis: "Fibromyalgia Agents", UMKC-DIC; August 2020.
4. Lippincott, Williams, Wilkins. PDR Electronic Library, Montvale NJ; 2019.
5. USPDI, Micromedex; 2020.
6. Drug Facts and Comparisons On-line; 2020.

*SmartPA PDL Proposal Form*

© 2020 Conduent Business Services, LLC. All rights reserved. Conduent™ and Conduent Design™ are trademarks of Conduent Business Services, LLC in the United States and/or other countries.

Other company trademarks are also acknowledged.